Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global leader in animal and cell model generation for preclinical research. The company develops antibody-based drugs and offers comprehensive preclinical pharmacology and gene-editing services, driving breakthroughs in oncology, immunology, and beyond. Biocytogen operates in the People's Republic of China, the United States, and internationally. Their core products include YH001, YH003, YH002, YH004, and YH008, undergoing clinical trials for various cancers. The company has partnerships with companies like Syncromune, RemeGen Co., Ltd., Chipscreen NewWay Biosciences, and Acepodia Inc. Biocytogen was incorporated in 2009 and is headquartered in Beijing, China. Biocytogen is dedicated to discovering and developing novel antibody therapeutics, including fully human antibodies. The company also has a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice HiTS Platform).